KIMAL
delivering healthcare innovation

KIMAL PLC
UNIT 10A CLAYFIELD ROAD,
WORCESTER SIX BUSINESS PARK,
WORCESTERSHIRE,
WR4 0AE, UK
T: +44 (0)845 437 9542
www.kimal.com

Medicines Recall – Kimal Procedure Packs containing BD ChloraPrep 1 ml Applicator and ChloraPrep Frepp TM 1.5 ml Applicators

5th June 2026

Dear Customer,

Our records indicate that you have purchased or received products that may be affected by the attached BD ChloraPrep Medicines recall notification.

Kimal Procedure Packs containing BD ChloraPrep 1 ml Applicator and ChloraPrep Frepp TM 1.5 ml Applicators

Kimal Procedure Pack Code	Affected Lot Numbers
K64874/P1	25E0699, 25K0767
K65289/PSP/P1	25E0130, 25E0584, 25K0825, 25M0224, 26C0760

Reason

BD has identified a potential issue affecting the integrity of the sterile barrier associated with wrinkling of the paper lidding material, which may extend into the seal area.

Where the sterile barrier has been compromised, there is a potential risk of microbial contamination during use.

Kimal has identified the above procedure packs as containing the affected BD ChloraPrep applicator lots.

Action Required

1. Review the attached **Urgent Medicines Recall Notice SUR-26-06093-FA** (Appendix 2).
2. Forward this notification to all relevant personnel within your organisation and to any organisation to which the affected products may have been supplied or transferred.
3. Identify and quarantine any affected procedure packs listed in Appendix 1.
4. Complete and return the attached **Customer Response Form** (Appendix 1) to **vigilance@kimal.com**, regardless of whether or not you have affected stock in your possession.

Time Period

A response is required by 19th June 2026, to complete Appendix 1.

Your prompt response is appreciated and will assist us in ensuring that all affected products are appropriately identified and controlled.

We apologise for any inconvenience this action may cause and thank you for your cooperation and understanding. These measures are being taken in the interests of patient safety and product quality.

Yours sincerely,

Amanda Makemson

Group Quality Assurance and Regulatory Affairs Director

Appendix 1 – Customer Response Form

BD ChloraPrep 1ml Applicator and ChloraPrep Frepp 1.5ml Applicators in Kimal Procedure Packs

Return this completed response form, whether or not you have any of the affected lots to **vigilance@kimal.com**

Customer Name and Address:	
Reply confirmation completed by: (Name)	
Title:	
Telephone Number:	
Email:	
Signature:	

We confirm:

☐We have read and understood the Medicines Recall
☐We have communicated the information to staff and other services / departments / units / facilities who need to know.

Action taken:

☐ We do not have any stock of the affected products
☐ We have Quarantined affected stock which requires collection

Kimal Procedure Pack Code	Affected Lot Numbers	Procedure Packs to be Returned (Qty)
K64874/P1	25E0699,	
	25K0767	
K65289/PSP/P1	25E0130	
	25E0584	
	25K0825	
	25M0224	
	26C0760	

Becton Dickinson UK Ltd
1030 Eskdale Road, Winnersh
Wokingham RG41 5TS
United Kingdom

Batch Recall

Direct Healthcare Professional Communication

ChloraPrep 1mL Applicator and ChloraPrep Frepp™ 1.5 ml Applicators

URGENT: MEDICINES RECALL SUR-26-06093-FA

ChloraPrep 1mL Applicator

ChloraPrep Frepp™ 1.5 ml Applicators

REF: 270480 and 270299

Type of Action: Removal (Recall)

Dear Customer

Summary

We wish to advise you that for below batches REF: 270480 BD ChloraPrep™ Clear - 1mL Applicator and REF 270299 ChloraPrep Frepp™ 1.5 ml Applicators- PL 05920/0002 - 0001 are being recalled.

This recall is going to Hospital level.

This action has been agreed with the Medicines and Healthcare Products Regulatory Agency (link)

ChloraPrep 1 mL and FREPP applicators with paper lidding may present a risk to sterile barrier integrity due to wrinkling of the lidding, which could increase the risk of microbial contamination.

Background

The reason for the recall is that BD has identified a potential risk to sterile barrier integrity associated with wrinkling of the paper lidding material, which may extend to the seal area. If the sterile barrier is compromised, there is a potential risk of microbial contamination during use.

Becton Dickinson UK Ltd
1030 Eskdale Road, Winnersh
Wokingham RG41 5TS
United Kingdom

This recall is limited to the batches listed below, which were manufactured using paper lidding. No other batches, including those manufactured with Tyvek lidding, are affected

Affected LOT batch numbers

Batch No.	Expiry Date	Pack Size	First Distributed
All lots with an expiry date up to and including 02/2028	All lots with an expiry date up to and including 02/2028	ChloraPrep 1mL Applicator: 60 applicators	11/09/2023
All lots with an expiry date up to and including 01/2028	All lots with an expiry date up to and including 01/2028	ChloraPrep Frepp™ 1.5 ml Applicators: 20 applicators	09/01/2024

Advice for Healthcare Professionals:

Stop supplying the affected batches. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

It is recommended that treating clinicians use their discretion in managing patients and/or users who may be at risk.

Actions to be taken

1. Please immediately discontinue use of the affected lots. Check all inventory locations within your facility and quarantine until disposal.
2. This recall notice should be shared with anyone who needs to be aware within your organization and forwarded to any organization where affected products have been transferred.
3. Complete the attached Response Form and return it to the contact noted on the form indicating whether or not you have any of the affected lots so that BD may acknowledge your receipt of this notification.
4. Indicate on the response form the quantity from the affected lots identified at your facility and confirm that this product inventory was returned.

Call for Reporting

Please continue to report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme.

Please report:

Becton Dickinson UK Ltd
1030 Eskdale Road, Winnersh
Wokingham RG41 5TS
United Kingdom

- all suspected ADRs that are serious or result in harm. Serious reactions are those that are fatal, life-threatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason
- all suspected ADRs associated with new drugs and vaccines identified by the black triangle ▼

You can report via:

- the Yellow Card website
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) for healthcare professionals

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

When reporting please provide as much information as possible, including information about medical history, any concomitant medication, timing onset, treatment dates, and product brand name.

Company contact point

For all medical information enquiries and information on this product, please email safetyinformation@bd.com, or telephone 08000437546. For stock control enquiries please email info@insightbio.com, or telephone 01707351330.

Yours faithfully

Sincerely,

Signed by:
Javier Franch
Signer Name: Javier Franch
Signing Reason: I approve this document
Signing Time: 02-Jun-2026 | 7:41:58 AM PDT
DBBE11F3FCA548408ECC00C94DFE28E5

Javier Franch
BD Associate Director, Global Pharma Quality